NO333290B1 - Farmasoytisk sammensetning for behandling og forebygging av prostatisk hyperplasi og prostatitt ved a anvende frukter av roystonea regia kongepalme. - Google Patents

Farmasoytisk sammensetning for behandling og forebygging av prostatisk hyperplasi og prostatitt ved a anvende frukter av roystonea regia kongepalme. Download PDF

Info

Publication number: NO333290B1
Authority: NO; Norway
Prior art keywords: fatty acids; fruits; pharmaceutical composition; roystonea; extract
Prior art date: 2003-03-20

Application number

NO20054847A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054847L (no

Inventor

Abilio Melquiades Laguna Granja

Eduardo Antonio Rodriguez Leyes

Rosa Maria Mas Ferreiro

Daisy Carbajal Quintana

Maria De Lourdes Arruzazabala Valmana

Vivian Molina Cuevas

Victor Luis Gonzalez Canavaciolo

Original Assignee

Dalmer Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-20

Filing date

2005-10-20

Publication date

2013-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO333290(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-20 Application filed by Dalmer Lab Sa filed Critical Dalmer Lab Sa

2005-10-20 Publication of NO20054847L publication Critical patent/NO20054847L/no

2013-04-29 Publication of NO333290B1 publication Critical patent/NO333290B1/no

Links

235000013399 edible fruits Nutrition 0.000 title claims abstract description 41
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
201000007094 prostatitis Diseases 0.000 title claims abstract description 8
240000007186 Roystonea regia Species 0.000 title claims abstract 5
238000011282 treatment Methods 0.000 title claims description 20
230000002265 prevention Effects 0.000 title claims 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 title abstract description 17
208000004403 Prostatic Hyperplasia Diseases 0.000 title abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 31
235000006595 Roystonea elata Nutrition 0.000 claims abstract description 27
241000899648 Roystonea Species 0.000 claims abstract description 16
201000004384 Alopecia Diseases 0.000 claims abstract description 14
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
238000000034 method Methods 0.000 claims abstract description 12
231100000360 alopecia Toxicity 0.000 claims abstract description 8
150000002148 esters Chemical class 0.000 claims abstract description 8
238000000605 extraction Methods 0.000 claims abstract description 7
230000007062 hydrolysis Effects 0.000 claims abstract description 7
238000006460 hydrolysis reaction Methods 0.000 claims abstract description 7
206010020112 Hirsutism Diseases 0.000 claims abstract description 6
235000021588 free fatty acids Nutrition 0.000 claims abstract description 6
238000001035 drying Methods 0.000 claims abstract description 4
239000003960 organic solvent Substances 0.000 claims abstract description 4
239000000284 extract Substances 0.000 claims description 44
235000014113 dietary fatty acids Nutrition 0.000 claims description 13
239000000194 fatty acid Substances 0.000 claims description 13
229930195729 fatty acid Natural products 0.000 claims description 13
150000004665 fatty acids Chemical class 0.000 claims description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
150000002632 lipids Chemical class 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
150000001298 alcohols Chemical class 0.000 claims description 4
150000004679 hydroxides Chemical class 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
239000005642 Oleic acid Substances 0.000 claims description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
150000002430 hydrocarbons Chemical class 0.000 claims description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
238000007127 saponification reaction Methods 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
235000011116 calcium hydroxide Nutrition 0.000 claims description 2
235000020778 linoleic acid Nutrition 0.000 claims description 2
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
229960004488 linolenic acid Drugs 0.000 claims description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
235000011118 potassium hydroxide Nutrition 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
235000011121 sodium hydroxide Nutrition 0.000 claims description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 3
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 3
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 3
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 3
239000002775 capsule Substances 0.000 claims 2
238000000227 grinding Methods 0.000 claims 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 2
238000002360 preparation method Methods 0.000 claims 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
239000005639 Lauric acid Substances 0.000 claims 1
235000021360 Myristic acid Nutrition 0.000 claims 1
235000021314 Palmitic acid Nutrition 0.000 claims 1
235000021319 Palmitoleic acid Nutrition 0.000 claims 1
235000021355 Stearic acid Nutrition 0.000 claims 1
229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
239000000839 emulsion Substances 0.000 claims 1
239000006210 lotion Substances 0.000 claims 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
229960002446 octanoic acid Drugs 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
239000002453 shampoo Substances 0.000 claims 1
238000007873 sieving Methods 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
239000000829 suppository Substances 0.000 claims 1
235000008947 Roystonea oleracea Nutrition 0.000 abstract description 3
229920006395 saturated elastomer Polymers 0.000 abstract description 3
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 46
210000002307 prostate Anatomy 0.000 description 26
229960003604 testosterone Drugs 0.000 description 23
244000208347 Roystonea elata Species 0.000 description 20
241001465754 Metazoa Species 0.000 description 14
240000006661 Serenoa repens Species 0.000 description 13
235000005318 Serenoa repens Nutrition 0.000 description 13
230000000694 effects Effects 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 12
239000010018 saw palmetto extract Substances 0.000 description 12
230000037396 body weight Effects 0.000 description 11
241000283973 Oryctolagus cuniculus Species 0.000 description 10
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
239000000843 powder Substances 0.000 description 8
229960003473 androstanolone Drugs 0.000 description 7
239000013642 negative control Substances 0.000 description 7
238000000585 Mann–Whitney U test Methods 0.000 description 6
235000015112 vegetable and seed oil Nutrition 0.000 description 6
239000008158 vegetable oil Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
239000003098 androgen Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000024963 hair loss Diseases 0.000 description 5
230000003676 hair loss Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
241000700159 Rattus Species 0.000 description 4
235000021022 fresh fruits Nutrition 0.000 description 4
238000004817 gas chromatography Methods 0.000 description 4
230000003779 hair growth Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000013641 positive control Substances 0.000 description 4
238000010298 pulverizing process Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
206010046555 Urinary retention Diseases 0.000 description 2
244000274883 Urtica dioica Species 0.000 description 2
235000009108 Urtica dioica Nutrition 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
229960004039 finasteride Drugs 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
206010029446 nocturia Diseases 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000009160 phytotherapy Methods 0.000 description 2
210000005267 prostate cell Anatomy 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960001712 testosterone propionate Drugs 0.000 description 2
239000005418 vegetable material Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
241001047505 Archontophoenix alexandrae Species 0.000 description 1
241000233788 Arecaceae Species 0.000 description 1
206010063408 Bladder hypertrophy Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960004607 alfuzosin Drugs 0.000 description 1
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
108010080146 androgen receptors Proteins 0.000 description 1
201000002996 androgenic alopecia Diseases 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
206010013990 dysuria Diseases 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000012977 invasive surgical procedure Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
210000001087 myotubule Anatomy 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011422 pharmacological therapy Methods 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229960002613 tamsulosin Drugs 0.000 description 1
229960001693 terazosin Drugs 0.000 description 1
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940010901 testosterone injection Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
230000014616 translation Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
201000002327 urinary tract obstruction Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Alternative & Traditional Medicine (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20054847A 2003-03-20 2005-10-20 Farmasoytisk sammensetning for behandling og forebygging av prostatisk hyperplasi og prostatitt ved a anvende frukter av roystonea regia kongepalme. NO333290B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU20030062A CU23256A1 (es)	2003-03-20	2003-03-20	EXTRACTO OBTENIDO A PARTIR DE FRUTOS DE ROYSTONEA REGIA UTILIZADO CONTRA LA HIPERPLASIA PROSTáTICA Y LA PROSTATITIS
PCT/CU2004/000004 WO2004082696A1 (es)	2003-03-20	2004-03-15	Composición farmacéutica y procedimiento para el tratamiento y prevención de la hiperplasia prostática y la prostatitis a partir de los frutos de roystones regia (palma real)

Publications (2)

Publication Number	Publication Date
NO20054847L NO20054847L (no)	2005-10-20
NO333290B1 true NO333290B1 (no)	2013-04-29

Family

ID=40210497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054847A NO333290B1 (no)	2003-03-20	2005-10-20	Farmasoytisk sammensetning for behandling og forebygging av prostatisk hyperplasi og prostatitt ved a anvende frukter av roystonea regia kongepalme.

Country Status (24)

Country	Link
US (3)	US20060228429A1 (da)
EP (1)	EP1623740B1 (da)
JP (1)	JP4693766B2 (da)
KR (1)	KR100758256B1 (da)
CN (1)	CN100366246C (da)
AT (1)	ATE394139T1 (da)
AU (1)	AU2004222693B2 (da)
BR (1)	BRPI0409056A (da)
CA (1)	CA2519410C (da)
CR (1)	CR8001A (da)
CU (1)	CU23256A1 (da)
DE (1)	DE602004013572D1 (da)
DK (1)	DK1623740T3 (da)
EC (1)	ECSP056028A (da)
ES (1)	ES2306999T3 (da)
IL (1)	IL170997A (da)
MX (1)	MXPA05009905A (da)
NO (1)	NO333290B1 (da)
NZ (1)	NZ542361A (da)
PT (1)	PT1623740E (da)
RU (1)	RU2331434C2 (da)
UA (1)	UA82224C2 (da)
WO (1)	WO2004082696A1 (da)
ZA (1)	ZA200507575B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4926395B2 (ja) *	2004-11-30	2012-05-09	学校法人名城大学	抗ｍｒｓａ用組成物
KR100769412B1 (ko) *	2006-09-13	2007-10-22	주식회사 벤스랩	Ｐｒ-119 복합생약 추출물을 함유하는 전립선 비대증의예방 및 치료용조성물
CA2795907A1 (en)	2009-04-09	2010-10-14	The Regents Of The University Of Colorado, A Body Corporate	Methods and compositions for inducing physiological hypertrophy
CU24143B1 (es) *	2012-06-19	2016-01-29	Cnic Ct Nac Investigaciones	Ingrediente activo para el tratamiento y la prevención de la inflamación y el estrés oxidativo, así como su procedimiento de obtención a partir de los frutos de acrocomina crispa y/o acrocomia aculeata
WO2016024168A1 (en) *	2014-08-12	2016-02-18	Institut de Recherche en Semiochimie et Ethologie Appliquee	Palmitoleic acid for use in inhibiting the attachment of sea lice to fish
KR102273967B1 (ko) *	2014-10-31	2021-07-08	(주)아모레퍼시픽	인삼씨유를 함유하여 전립선 비대증을 예방 및 치료하는 조성물
JP2017214342A (ja) *	2016-06-02	2017-12-07	日清オイリオグループ株式会社	排尿障害の予防用又は改善用組成物
CN111050763B (zh) *	2017-12-26	2024-10-11	福冈大太朗	用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物
CA3089480C (en)	2018-01-26	2025-05-27	Fluidx Medical Technology, Inc.	APPARATUS AND METHOD FOR USING COMPLEX COACERVATES WITH IN SITU SOLIDIFICATION FOR VASCULAR OCLUSION
EP4082518A1 (en)	2021-04-28	2022-11-02	Cnce Innovacion, S.L.	Fatty acid compositions for the treatment and prevention of hair loss and alopecia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU21519A1 (en) *	1983-03-23	1987-06-09	Inst De Quimica Y Biolog Ex	Procedure to facilitate the grinding of roystonea regia fruits
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
CN1184670A (zh) *	1997-12-23	1998-06-17	张冰	一种治疗前列腺增生、前列腺炎的药物组合物
RU2140265C1 (ru) *	1998-10-27	1999-10-27	Чернобаев Николай Евгеньевич	Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы

2003
- 2003-03-20 CU CU20030062A patent/CU23256A1/es unknown
2004
- 2004-03-15 EP EP04720576A patent/EP1623740B1/en not_active Expired - Lifetime
- 2004-03-15 JP JP2006504216A patent/JP4693766B2/ja not_active Expired - Fee Related
- 2004-03-15 RU RU2005130746/15A patent/RU2331434C2/ru not_active Application Discontinuation
- 2004-03-15 DE DE602004013572T patent/DE602004013572D1/de not_active Expired - Lifetime
- 2004-03-15 BR BRPI0409056-0A patent/BRPI0409056A/pt not_active IP Right Cessation
- 2004-03-15 AT AT04720576T patent/ATE394139T1/de active
- 2004-03-15 UA UAA200508900A patent/UA82224C2/uk unknown
- 2004-03-15 ES ES04720576T patent/ES2306999T3/es not_active Expired - Lifetime
- 2004-03-15 AU AU2004222693A patent/AU2004222693B2/en not_active Expired
- 2004-03-15 WO PCT/CU2004/000004 patent/WO2004082696A1/es not_active Ceased
- 2004-03-15 US US10/549,740 patent/US20060228429A1/en not_active Abandoned
- 2004-03-15 MX MXPA05009905A patent/MXPA05009905A/es active IP Right Grant
- 2004-03-15 DK DK04720576T patent/DK1623740T3/da active
- 2004-03-15 CA CA2519410A patent/CA2519410C/en not_active Expired - Fee Related
- 2004-03-15 KR KR1020057017600A patent/KR100758256B1/ko not_active Expired - Lifetime
- 2004-03-15 PT PT04720576T patent/PT1623740E/pt unknown
- 2004-03-15 NZ NZ542361A patent/NZ542361A/xx not_active IP Right Cessation
- 2004-03-15 CN CNB2004800071887A patent/CN100366246C/zh not_active Expired - Lifetime
2005
- 2005-09-19 ZA ZA200507575A patent/ZA200507575B/xx unknown
- 2005-09-20 EC EC2005006028A patent/ECSP056028A/es unknown
- 2005-09-20 CR CR8001A patent/CR8001A/es unknown
- 2005-09-20 IL IL170997A patent/IL170997A/en not_active IP Right Cessation
- 2005-10-20 NO NO20054847A patent/NO333290B1/no not_active IP Right Cessation
2009
- 2009-10-08 US US12/575,575 patent/US20100021574A1/en not_active Abandoned
- 2009-10-08 US US12/575,584 patent/US20100022649A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2519410C (en)	2011-04-26
BRPI0409056A (pt)	2006-03-28
HK1084059A1 (en)	2006-07-21
KR100758256B1 (ko)	2007-09-13
RU2331434C2 (ru)	2008-08-20
PT1623740E (pt)	2008-08-12
ZA200507575B (en)	2007-03-28
DK1623740T3 (da)	2008-09-08
CA2519410A1 (en)	2004-09-30
AU2004222693A1 (en)	2004-09-30
KR20050115920A (ko)	2005-12-08
RU2005130746A (ru)	2006-06-10
NZ542361A (en)	2009-10-30
JP2006520331A (ja)	2006-09-07
CR8001A (es)	2006-04-21
IL170997A (en)	2010-04-15
ECSP056028A (es)	2006-01-27
NO20054847L (no)	2005-10-20
WO2004082696A1 (es)	2004-09-30
AU2004222693B2 (en)	2010-08-12
ES2306999T3 (es)	2008-11-16
DE602004013572D1 (de)	2008-06-19
US20060228429A1 (en)	2006-10-12
US20100022649A1 (en)	2010-01-28
US20100021574A1 (en)	2010-01-28
JP4693766B2 (ja)	2011-06-01
UA82224C2 (uk)	2008-03-25
CU23256A1 (es)	2008-01-24
ATE394139T1 (de)	2008-05-15
EP1623740B1 (en)	2008-05-07
CN100366246C (zh)	2008-02-06
MXPA05009905A (es)	2006-03-21
AU2004222693A2 (en)	2004-09-30
EP1623740A1 (en)	2006-02-08
CN1761476A (zh)	2006-04-19

Legal Events

Date	Code	Title	Description
2014-11-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20100022649A1 (en)	2010-01-28	Pharmaceutical Composition and Procedure to Treat and Prevent Prostatic Hyperplasia and Prostatitis From the Royal Palm (Roystonea regia) Fruits
Kalu et al.	2016	Effect of kolaviron, a biflavanoid complex from Garcinia kola on some biochemical parameters in experimentally induced benign prostatic hyperplasic rats
Shin et al.	2012	Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia
US20190117723A1 (en)	2019-04-25	Compositions based on plant extracts for inhibition of the 5-alpha reductase
CN101879156B (zh)	2013-01-30	一种药物组合物及其应用
Monji et al.	2016	Investigation of uterotonic properties of Ananas comosus extracts
Orieke et al.	2020	Gastrointestinal and uterine smooth muscles relaxant and anti-inflammatory effects of Corchorus olitorius leaf extract in laboratory animal models
CN111265503B (zh)	2021-03-12	一种抑制5α-还原酶活性的组合物及其应用
JPH05194250A (ja)	1993-08-03	サバルセルラタのリピド抽出物の酸分画から導かれた新規薬学的組成物及びその組成物を製造する方法
Ogunlakin et al.	2023	Ameliorative effect of Kigelia africana (Lam.) Benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat
Maccagnano et al.	2006	A critical analysis of Permixon™ in the treatment of lower urinary tract symptoms due to benign prostatic enlargement
Hai-Nan et al.	2015	Inhibitory effects of TripTripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats
Gutiérrez et al.	2011	One year oral Toxicity of D-004, a lipid extract from Roystonea regia fruits, in Sprague Dawley rats
HK1084059B (en)	2008-07-04	Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits
WO2015063751A1 (en)	2015-05-07	Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems
Sarwar et al.	2014	Piper longum hexane fraction induces infertility by modulation of inflammatory mediators and gonadotripin insufficiency in female rats
Kaur et al.	2023	Anti-fertility and abortifacient activity of hydroalcoholic fruit pulp extract of Tamarindus indica
KR20220129833A (ko)	2022-09-26	노르갈란타민을 포함하는 간 손상의 예방 또는 치료용 조성물
Essiet et al.	2016	Effect of Ethanol Root Bark Extract of Salacia lehmbachii Loes on Male Reproductive Hormones in Albino Rats
Saraswathi et al.	2012	Protective effect of Symplocos racemosa bark on cold restraint stress induced reproductive changes in female rats
Motamed et al.	2020	Effects of Hydro-alcoholic Extract of Pumpkin Seeds on Oogenesis Pathway, Liver, and Kidney of Female Rats
JP2020200325A (ja)	2020-12-17	牛蒡抽出物の使用
Azizi et al.	2021	Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 1; peer
FR2877577A1 (fr)	2006-05-12	Extraits de fruits d'astrocaryum aculeatum a visee anti hypertrophie benigne de la prostate, anti inflammatoire et anti oxydante
KASHINATH	2019	EFFECT OF ALOE VERA GEL AND MINT TEA ON LETROZOLE INDUCED POLYCYSTIC OVARY SYNDROME IN WISTAR RATS